Aptevo Therapeutics and the ADAPTIR™ (Modular Protein Technology) Platform: The Future of Immuno-oncology

Aptevo Therapeutics is a biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. We also have four commercial products that generate revenue in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.


Recent Updates

Stock Details Stock Summary | APVO | Nasdaq $2.00 + 0.03 (1.52%)
Volume: 95,162
Updated April 27, 2017  4:00 p.m. ET
IR Contacts Primary IR Contact
Stacey L. Jurchison
Senior Director, Investor Relations & Corporate Communications
Phone: 206.859.6628
E-mail: jurchisons@apvo.com

Hemostasis and Thrombosis Research Society 2017 Scientific Symposium
American Association for Cancer Research 2017 Annual Meeting
Aptevo Therapeutics Inc at 29th Annual ROTH Conference